Edition:
United States

Santhera Pharmaceuticals Holding AG (SANN.S)

SANN.S on Swiss Exchange

15.80CHF
11:30am EDT
Change (% chg)

CHF-0.20 (-1.25%)
Prev Close
CHF16.00
Open
CHF16.20
Day's High
CHF16.20
Day's Low
CHF15.50
Volume
10,673
Avg. Vol
11,321
52-wk High
CHF41.15
52-wk Low
CHF14.52

Select another date:

Mon, Oct 15 2018

BRIEF-Santhera Gets Positive Opinion For Orphan Drug Designation In EU For Pol6014 In Cystic Fibrosis

* SANTHERA RECEIVES POSITIVE OPINION FOR ORPHAN DRUG DESIGNATION IN THE EU FOR POL6014 IN CYSTIC FIBROSIS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Santhera Hopes for Good News to Lift Shares, Pave Way For Capital Hike

* SAYS EXPECTS 50 MILLION SFR SALES OF RAXONE WITHIN 2-3 YEARS‍​

Santhera lifts forecast amid cash burn, trial setbacks

ZURICH, Sept 4 Santhera lifted its full-year 2018 sales forecast slightly but quickly drew down cash reserves in the first half, as the Swiss drugmaker continued efforts to make a success of its main drug despite regulatory and trial setbacks.

BRIEF-Santhera Pharmaceuticals Holding H1 Net Result Of CHF -27.4 Mln

* 1H 2018 SALES OF CHF 16.0 MILLION, INCREASE OF 48% COMPARED TO 1H 2017

BRIEF-Santhera: MHRA Renews Early Access Option For Raxone For Duchenne

* UK'S MHRA RENEWS EARLY ACCESS TO MEDICINES SCHEME SCIENTIFIC OPINION FOR SANTHERA'S RAXONE® (IDEBENONE) IN DUCHENNE MUSCULAR DYSTROPHY Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Select another date: